Previous 10 | Next 10 |
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
ChromaDex Corporation (CDXC) is expected to report $-0.03 for Q3 2023
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023...
The global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex, and the #1 selling pet supplement brand in the USA*, Zesty Paws ® , debut cellular health supplement featuring ChromaDex’s industry leading healthy aging ingredient, Nia...
Celebrating a significant achievement in NAD + research, these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders ChromaDex Corp. (N...
This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and healthy ...
2023-08-09 20:32:05 ET ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript August 09, 2023 04:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Con...
2023-08-09 16:27:15 ET ChromaDex press release ( NASDAQ: CDXC ): Q2 GAAP EPS of -$0.03 beats by $0.01 . Revenue of $20.3M (+21.6% Y/Y) beats by $0.78M . Total net sales were $20.3 million, with $16.9 million from Tru Niagen, up 21% and 16% from the prior year q...
Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended June 30, 2023. ChromaDex Corp. (NASDAQ:CDXC) today announc...
This partnership positions Tru Niagen for accelerated global expansion given nearly 90% of iHerb sales are outside of the U.S. ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destina...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. ChromaDex Corp. (NASDAQ:CDXC) today anno...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
New ingredient collaboration debuts Solgar’s first NAD + boosting supplement and reinforces NIAGEN as the gold standard in the NAD + supplement category ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and h...